Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Male and non-pregnant, non breast-feeding female outpatients at least 18 years of age (no upper age limit).~* 2. History of constipation; the subject reports, on average, two or fewer spontaneous bowel movements per week that result in a feeling of complete evacuation and or one or more of the following for at least 6 months before the selection visit:~  1. very hard (little balls) and/or hard stools at least a quarter of the stools~ 2. sensation of incomplete evacuation following at least a quarter of the stools~ 3. straining at defecation at least a quarter of the time. The above criteria are only applicable for spontaneous bowel movements, i.e., not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.~Subjects who never have spontaneous bowel movements are considered to be constipated and are eligible for the trial.~Exclusion Criteria:~* 1. Subjects in whom constipation is thought to be drug-induced, or subjects using any disallowed medication.~* 2. Subjects suffering from endocrine disorders, metabolic disorders or neurologic disorders.~* 3. Subjects with a megacolon/megarectum or a diagnosis of pseudo-obstruction.~* 4. Constipation as a result of surgery.~* 5. Known or suspected organic disorders of the large bowel, i.e. obstruction, carcinoma, or inflammatory bowel disease.~* 6. Subjects with severe and clinically uncontrolled cardiovascular, liver, or lung disease, neurologic or psychiatric disorders (including active alcohol or drug abuse), cancer or AIDS, and other gastrointestinal or endocrine disorders.~* 7. Subjects with impaired renal function.~* 8. Subjects with clinically significant abnormalities of haematology, urinalysis, or blood chemistry.~* 9. Females of child-bearing potential without adequate contraceptive protection during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Prucalopride 2 mg
- 3 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: ACTIVE_COMPARATOR): Prucalopride 4 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).